CagA status and successful eradication of Helicobacter pylori [3]

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 8, 2006, Pages 1261-1263

  Treiber, G ^a   Malfertheiner, P ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN;

CLINICAL PRACTICE; DYSPEPSIA; HELICOBACTER PYLORI; INFECTION CONTROL; LETTER; PEPTIC ULCER; PRIORITY JOURNAL; RISK REDUCTION;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 33748892420     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03097.x     Document Type: Letter

References (5)

1. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: importance of cagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 273-80.
2. Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003; 17 (Suppl. B): 53B-7B (review).
3. Treiber G, Klotz U, Malfertheiner P. Treatment and dosing of Helicobacter pylori infection - when pharmacology meets clinic. Expert Opin Pharmacother 2006 (in press).
4. Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-9.
5. Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-73.